Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Laura Mezquita(Hospital Clínic de Barcelona), Collin M. Blakely(City College of San Francisco), Chad V. Pecot(University of North Carolina at Chapel Hill), Melina E. Marmarelis(University of Pennsylvania), Matthew D. Hellmann(AstraZeneca (United States)), Pradnya D. Patil(Cleveland Clinic), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Matthias Scheffler(TH Köln - University of Applied Sciences), Fabrizio Tabbò(Ospedale San Pietro Fatebenefratelli), Joseph C. Murray(Johns Hopkins University), Anastasios Dimou(Mayo Clinic), Catherine A. Shu(Columbia University Irving Medical Center), Justin F. Gainor(Harvard University), Jonathan W. Riess(University of California Davis Medical Center), Jessica A. Hellyer(Montrose Center), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Vassiliki A. Papadimitrakopoulou(Pfizer (United States))
Cited by 102
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k